firsocostat

Firsocostat is an oral, liver-targeted small molecule inhibitor of acetyl-CoA carboxylase (ACC), an enzyme that catalyzes the conversion of acetyl-CoA to malonyl-CoA, a key step in de novo lipogenesis. By inhibiting ACC, firsocostat reduces hepatic fat accumulation and is being developed primarily for the treatment of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). The drug was originally discovered by Nimbus Therapeutics and later acquired by Gilead Sciences for further development. Firsocostat has demonstrated significant reduction in liver fat content in phase 2 clinical trials but has also been associated with increased plasma triglycerides. Its mechanism targets metabolic dysfunctions central to NASH pathogenesis[1][3][5][7].

Other names

firsocostat